Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Primary treatment and prognostic factors of carcinosarcoma of the ovary, fallopian tube, and peritoneum: a Taiwanese Gynecologic Oncology Group Study.

Lu CH, Chen IH, Chen YJ, Wang KL, Qiu JT, Lin H, Lin WC, Liou WS, Huang YF, Lin YS, Tee YT, Hung YC.

Int J Gynecol Cancer. 2014 Mar;24(3):506-12. doi: 10.1097/IGC.0000000000000083.

PMID:
24557435
2.

"Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".

Rauh-Hain JA, Birrer M, Del Carmen MG.

Gynecol Oncol. 2016 Aug;142(2):248-54. doi: 10.1016/j.ygyno.2016.06.003. Epub 2016 Jun 16. Review.

PMID:
27321238
3.

Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).

Dahm-Kähler P, Borgfeldt C, Holmberg E, Staf C, Falconer H, Bjurberg M, Kjölhede P, Rosenberg P, Stålberg K, Högberg T, Åvall-Lundqvist E.

Gynecol Oncol. 2017 Jan;144(1):167-173. doi: 10.1016/j.ygyno.2016.10.039. Epub 2016 Nov 3.

PMID:
27817932
4.

Serous carcinoma of the ovary, fallopian tube, or peritoneum presenting as lymphadenopathy.

Euscher ED, Silva EG, Deavers MT, Elishaev E, Gershenson DM, Malpica A.

Am J Surg Pathol. 2004 Sep;28(9):1217-23.

PMID:
15316322
5.

Clinical outcomes of uterine carcinosarcoma: results of 94 patients.

Gokce ZK, Turan T, Karalok A, Tasci T, Ureyen I, Ozkaya E, Kose MF, Tulunay G.

Int J Gynecol Cancer. 2015 Feb;25(2):279-87. doi: 10.1097/IGC.0000000000000347.

PMID:
25611900
6.

Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.

Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E.

Gynecol Oncol. 2008 Jan;108(1):136-40. Epub 2007 Oct 23.

PMID:
17936342
7.

Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.

Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, Ferron G, Stoeckle E, Pomel C, Vinet B, Chereau E, Bergzoll C, Querleu D.

Int J Gynecol Cancer. 2012 Oct;22(8):1337-43.

PMID:
22964527
8.

Prognostic role of early versus late onset of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube.

Sehouli J, Olschewski J, Schotters V, Fotopoulou C, Pietzner K.

Ann Oncol. 2013 Dec;24(12):3024-8. doi: 10.1093/annonc/mdt398. Epub 2013 Oct 14.

PMID:
24130264
9.

Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.

Rosendahl M, Høgdall CK, Mosgaard BJ.

Int J Gynecol Cancer. 2016 May;26(4):680-7. doi: 10.1097/IGC.0000000000000675.

PMID:
26937751
10.

Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.

Gadducci A, Landoni F, Sartori E, Maggino T, Zola P, Gabriele A, Rossi R, Cosio S, Fanucchi A, Tisi G.

Gynecol Oncol. 2001 May;81(2):150-9.

PMID:
11330942
11.

Carcinosarcoma of the ovary-a case series.

Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, Mutch DG, Johnson GA, Walker JL, Mannel RS.

Gynecol Oncol. 2006 Jan;100(1):128-32. Epub 2005 Oct 5.

PMID:
16213011
12.

A single-institution evaluation of factors important in fallopian tube carcinoma recurrence and survival.

Shamshirsaz AA, Buekers T, Degeest K, Bender D, Zamba G, Goodheart MJ.

Int J Gynecol Cancer. 2011 Oct;21(7):1232-40. doi: 10.1097/IGC.0b013e318220fc46.

PMID:
21720254
13.

Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan.

Chao KC, Chen YJ, Juang CM, Lau HY, Wen KC, Sung PL, Fang FY, Twu NF, Yen MS.

Taiwan J Obstet Gynecol. 2013 Mar;52(1):81-4. doi: 10.1016/j.tjog.2012.10.003.

14.

The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries.

Ayhan A, Guvenal T, Salman MC, Ozyuncu O, Sakinci M, Basaran M.

Gynecol Oncol. 2005 Aug;98(2):235-41.

PMID:
15982725
15.

Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma.

Signorelli M, Chiappa V, Minig L, Fruscio R, Perego P, Caspani G, Battistello M, Colombo N.

Int J Gynecol Cancer. 2009 Aug;19(6):1142-6. doi: 10.1111/IGC.0b013e3181a8ef22.

PMID:
19820383
16.

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS.

Gynecol Oncol. 2012 Jun;125(3):621-4. doi: 10.1016/j.ygyno.2012.03.027. Epub 2012 Mar 21.

PMID:
22446622
17.
18.

[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].

Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Chinese.

PMID:
22883524
19.

Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.

Chang SJ, Bristow RE, Ryu HS.

Gynecol Oncol. 2012 Sep;126(3):381-6. doi: 10.1016/j.ygyno.2012.05.014. Epub 2012 May 18.

PMID:
22609747
20.

Clinical and survival analysis of 36 cases of primary fallopian tube carcinoma.

Ma Y, Duan W.

World J Surg Oncol. 2014 Oct 12;12:311. doi: 10.1186/1477-7819-12-311.

Supplemental Content

Support Center